イマティクス―免疫細胞ベースのがん治療薬をBMSと開発へ―
独バイオ医薬品企業イマティクスは2日、米製薬大手ブリストル・マイヤーズ・スクイブ(BMS)とがん治療薬開発で協業合意したと発表した。免疫細胞の一種であるT細胞ベースの製品を共同開発する。イマティクスが持つ養子細胞免疫治療 […]
独バイオ医薬品企業イマティクスは2日、米製薬大手ブリストル・マイヤーズ・スクイブ(BMS)とがん治療薬開発で協業合意したと発表した。免疫細胞の一種であるT細胞ベースの製品を共同開発する。イマティクスが持つ養子細胞免疫治療 […]
Cookie | 期間 | 説明 |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |